NORTH CHARLESTON,Argolyn Bioscience continues to expand its intellectual property portfolio for drug development.

The South Carolina-based firm said Wednesday that had recently received its fifth patent related to peptide-based drug candidates.

The patent is based on research by Thomas Dix and was cited as “positively charged non-natural amino acids, methods of making and using thereof in peptides.”

Dix has licensed his technology to Argolyn. Dix is chief scientific officer at Argolyn and is associate professor of pharmaceutical sciences in the College of Pharmacy at the Medical University of South Carolina.

“This patent completes the second series of compounds devised by Dr. Dix, and creates a sizeable footprint around the intellectual property that is key to Argolyn’s future growth,” said Pearce Gilbert, president of Argolyn, in a statement. “Foreign equivalents are still pending, but the success in prosecuting the US cases suggests a good probability that the foreign cases also will issue in due course.”

Argolyn has one drug in preclinical development and is working on several others.